LLP2A-Bisphosphonate Conjugates for Pre-Collapse Osteonecrosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Osteonecrosis, a condition characterized by impaired blood supply leading to bone death, often results in bone collapse and joint destruction, with limited effective treatments available, particularly for traumatic and non-traumatic forms.

Innovation Solution

Administration of a pharmaceutical composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug, such as LLP2A-Ale, to increase vascular density and prevent cell death in osteonecrotic tissues, optionally combined with mesenchymal stem cells and anabolic agents like PTH.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for osteonecrosis, then the condition can be managed, but effective treatment is limited and bone collapse occurs

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidbone strength

Core Design Contradiction:

ReliabilityVSStrength

Solution Approach 1:

The patent combines an LLP2A peptidomimetic ligand with a bisphosphonate drug to create a conjugate that simultaneously targets both angiogenesis and bone remodeling pathways, achieving superior treatment effectiveness compared to conventional single-agent therapies

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The conjugate of the peptidomimetic ligand and bisphosphonate functions as a composite therapeutic agent, integrating multiple mechanisms of action (angiogenesis promotion and osteoblast stimulation) within a single molecular entity to restore bone strength

Inventive Principle:

Principle #40Composite materials

2Loss of time

If osteonecrosis is left untreated, then no intervention is needed, but bone collapse and joint destruction occur

Engineering Contradiction:

Improvetime for treatment interventionVSAvoidbone collapse

Core Design Contradiction:

Loss of timeVSObject-affected harmful factors

Solution Approach 1:

The patent enables early intervention by detecting osteonecrotic lesions through MRI before bone collapse occurs, allowing administration of the conjugate therapy in the pre-collapse stage to prevent the harmful progression of the disease

Inventive Principle:

Principle #10Preliminary action

3Quantity of substance

If the LLP2A-bisphosphonate conjugate is administered, then vascular density increases and cell death is prevented, but the mechanism is complex

Engineering Contradiction:

Improvevascular densityVSAvoidmechanism complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The conjugate is segmented into two functional components: the LLP2A peptidomimetic ligand that binds to CD44 on endothelial cells to promote angiogenesis, and the bisphosphonate moiety that stimulates osteoblast activity, with each segment contributing a specific therapeutic function

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The LLP2A-bisphosphonate conjugate increases vascular density, reduces osteonecrotic lesion size, and prevents cell death, effectively treating osteonecrosis and potentially reversing bone damage.

Implementation Method 1

increases vascular density in an osteonecrotic tissue

Methodology Applied

Scientific EffectAngiogenesis:

Implementation Method 2

prevents cell death in an osteonecrotic tissue

Methodology Applied

Scientific EffectApoptosis inhibition:

Data Source

PatentUS12569506B2Methods of treating osteonecrosis with LLP2A-bisphosphonate compounds

Publication Date: 2026.03.10 RGT UNIV OF CALIFORNIA

AI summary

Methods of treating osteonecrosis in a subject are provided. In some embodiments, the method comprises administering to a subject having or suspected of having osteonecrosis a pharmaceutical composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug. In some embodiments, the pharmaceutical composition comprises a conjugate of LLP2A and alendronate (LLP2A-Ale). In some embodiments, the method further comprises administering exogenous mesenchymal stem cells.